These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

688 related items for PubMed ID: 30813769

  • 1. Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.
    Garland SG, Smith SM, Gums JG.
    Ann Pharmacother; 2019 Sep; 53(9):933-939. PubMed ID: 30813769
    [Abstract] [Full Text] [Related]

  • 2. Erenumab: First Global Approval.
    Markham A.
    Drugs; 2018 Jul; 78(11):1157-1161. PubMed ID: 29968151
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J.
    Lancet; 2018 Nov 24; 392(10161):2280-2287. PubMed ID: 30360965
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.
    Goadsby PJ, Paemeleire K, Broessner G, Brandes J, Klatt J, Zhang F, Picard H, Lenz R, Mikol DD.
    Cephalalgia; 2019 Jun 24; 39(7):817-826. PubMed ID: 30982348
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of erenumab in women with a history of menstrual migraine.
    Pavlovic JM, Paemeleire K, Göbel H, Bonner J, Rapoport A, Kagan R, Zhang F, Picard H, Mikol DD.
    J Headache Pain; 2020 Aug 03; 21(1):95. PubMed ID: 32746775
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A Controlled Trial of Erenumab for Episodic Migraine.
    Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA.
    N Engl J Med; 2017 Nov 30; 377(22):2123-2132. PubMed ID: 29171821
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Erenumab for episodic migraine.
    Datta A, Gupta S, Maryala S, Aggarwal V, Chopra P, Jain S.
    Pain Manag; 2022 Jul 30; 12(5):587-594. PubMed ID: 35313740
    [Abstract] [Full Text] [Related]

  • 18. Vascular safety of erenumab for migraine prevention.
    Kudrow D, Pascual J, Winner PK, Dodick DW, Tepper SJ, Reuter U, Hong F, Klatt J, Zhang F, Cheng S, Picard H, Eisele O, Wang J, Latham JN, Mikol DD.
    Neurology; 2020 Feb 04; 94(5):e497-e510. PubMed ID: 31852816
    [Abstract] [Full Text] [Related]

  • 19. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R, Salerno A, Torelli P, Albanese M, Carnevale A, Bono F, D'Amico D, Filippi M, Altamura C, Vernieri F, EARLY Study Group.
    Headache; 2021 Oct 04; 61(9):1351-1363. PubMed ID: 34309862
    [Abstract] [Full Text] [Related]

  • 20. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
    Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Cheng S, Numachi Y, Peng C, Xue F, Mikol DD.
    Headache; 2021 Apr 04; 61(4):653-661. PubMed ID: 33764538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.